An interventional study of Alternative rehabilitation strategies and Usual Care in Deafness, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Deafness with a site in United States — 19 open to participants now, 22 under way, 1 of them phase 3. Deafness · United States.
Among the 63 studies in Deafness with a site in United States, this one is the 9th largest by enrollment of the 44 interventional ones that give a count, is one of 5 that started in 2024, is one of 31 with no phase, and was the 52nd registered.
161 studies on the registry are indexed under Deafness; 46 are open to participants now.
Browse Deafness studies →19 of the 63 studies in Deafness with a site in United States are open now. Recruiting first, the newest first:
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18–80
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
Craig D. Workman, PhD · Sites in United States
Ages 18–99
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18–85
Eli Lilly and Company · Sites in United States, Canada, Taiwan and 1 more country
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Deafness studies recruiting now, 11 (37%) set no upper age limit and 10 (33%) stop at 75 or younger; 19 take children under 18; 5 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 1997; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 42 across 107 interventional studies indexed under Deafness.
Median enrollment 41 across the 44 interventional studies, 249 across the 19 observational. Of the 34 that completed or were terminated, 14 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 63 have an industry lead sponsor. The 10 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
NYU Langone Health has 5 studies filed under Deafness — fewer than ten, so there is no comparison to draw.
9 of the studies in Deafness with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT06960616Massachusetts Eye and Ear InfirmaryImproving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy | 2026-11-26 |
| NCT01694940Columbia UniversityNorth American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC) | 2026-12-31 |
| NCT05203302NYU Langone HealthNovel Coding Strategies for Children With Cochlear Implants | 2027-01-01 |
| NCT06901674NYU Langone HealthStimulating the Cochlear Apex Without Longer Electrodes | 2027-01-01 |
Add all 9 to your calendar (.ics) → With an account.
Among the 63 studies in Deafness with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
During a primary care visit, investigators will screen and identify participants with hearing loss and then randomize to a) counseling on accessible assistive listening devices or b) referral to traditional audiology care pathway alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who screened positive for hearing loss and were randomized into the counselling on alternative rehabilitation strategies intervention arm.
Behavioral: Alternative rehabilitation strategies
Patients who screened positive for hearing loss and were randomized into the usual care audiology pathway control arm alone.
Behavioral: Usual Care
Counseling intervention.
Usual care audiology pathway.
Number of Potential Participants Approached
Time frame: Up to Month 3
Number of Potential Participants Screened
Time frame: Up to Month 3
Percentage of Screened Participants with Hearing Loss
Time frame: Up to Month 3
Percentage of Intervention Arm Participants who Complete Counseling Session
Time frame: Up to Month 3
Percentage of Participants who Respond to Outreach to Confirm Recommendations within 72 Hours
Time frame: Up to Month 3
Percentage of Participants who Respond to 3-Month Follow-Up
Time frame: Month 3
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The de-identified participant data from the final research dataset used in the published manuscript will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: David.friedmann@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to David.friedmann@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
Ran from Feb 2024 to primary completion in Aug 2025, 18 months.
Of 50 non-industry interventional studies with no phase under Deafness, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20. This study's 18 months is below that.
Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 17.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jan 2026 → Aug 2025 and completion Jan 2026 → Nov 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.